Clinical studies of monoclonal antibodies against the proprotein convertase subtilisin / kexin type 9
Abstract
The review presents the current data of scientific literature about different phases of clinical trials of monoclonal antibodies against the proprotein convertase subtilisin/kexin type 9 (PCSK9). The results of completed clinical trials and the review of clinical studies that will be complete in the 2015–2018’s are presented.
About the Authors
K. S. Astrakova
Institute of Internal and Preventive Medicine
Russian Federation
Russian Federation
630089
Boris Bogatkov str., 175/1
Novosibirsk
Yu. I. Ragino
Institute of Internal and Preventive Medicine
Russian Federation
Russian Federation
630089
Boris Bogatkov str., 175/1
Novosibirsk
E. V. Shakhtshneider
Institute of Internal and Preventive Medicine
Russian Federation
Russian Federation
630089
Boris Bogatkov str., 175/1
Novosibirsk
M. I. Voevoda
Institute of Internal and Preventive Medicine
Russian Federation
Russian Federation
630089
Boris Bogatkov str., 175/1
Novosibirsk
References
1. Ridker P. M. LDL cholesterol: controversies and future therapeutic directions // Lancet. 2014. Vol. 384. P. 607–617.
2. Stein E. A., Mellis S., Yancopoulos G. D. et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol // N. Engl. J. Med. 2012. Vol. 366, N 12. P. 1108–1118.
3. Dias C. S., Shaywitz A. J., Wasserman S. M. et al. Effects of AMG145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo- controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins // J. Am. Coll. Cardiol. 2012. Vol. 60, N 19. P. 1888–1898.
4. Clinical Trials gov. The Evaluation of PF-04950615 (RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). – http://clinicaltrials.gov/ct2/show/NCT01975389?termјSPIRE-2&rankј1, Published March 4, 2014 (accessed 19. 03. 14.).
5. Mason I. Pharma Times on line, Antibody lipid treatments enter final furlong. – https://www.pharmatimes.com/news/antibody_lipid_treatments_enter_final_furlong_1005620
6. Dadu R. T., Ballantyne C. M. Lipid lowering with PCSK9 inhibitors // Nat. Rev. Cardiol. 2014. Vol. 84. P. 1–13.
7. Ecker-Schlipf B. Hyperlipidemia. New treatment option with Evolocumab // Med. Monatsschr. Pharm. 2014. Vol. 37, N 7. P. 271–272.
8. Chan J. C., Piper D. E., Cao Q. et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates // Proc. Natl. Acad. Sci. USA. 2009. Vol. 106. P. 9820–9825.
9. Stein E. A., Honarpour N., Wasserman S. M. et al. Effect of the, proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia // Circulation. 2013. Vol. 128, N 19. P. 2113–2120.
10. Raal F., Scott R., Somaratne R. et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial // Circulation. 2012. Vol. 126, N 20. P. 2408–2417.
11. Sullivan D., Olsson A. G., Scott R. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial // JAMA. 2012. Vol. 308, N 23. P. 2497–2506.
12. Koren M. J., Scott R., Kim J. B. et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexintype 9 as monotherapy in patients with hypercholesterolaemia(MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study // Lancet. 2012. Vol. 380, N 9858. P. 1995–2006.
13. Giugliano R. P., Desai N. R., Kohli P. et al. Efficacy, safety, and tolerability of amonoclonal antibody to proprotein convertase subtilisin/ kexin type 9 in combination with a statin in patients with hypercho lesterolaemia(LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study // Ibid. P. 2007–2017.
14. Koren M. J., Giugliano R. P., Raal F. J. et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial // Circulation. 2014. Vol. 129, N 2. P. 234–243.
15. Hirayama A., Honarpour N., Yoshida M. et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in Hypercholesterolemic, statin-treated japanesepatients at high cardiovascular risk // Circ. J. 2014. Vol. 78, N 5. P. 1073–1082.
16. Sahebkar A., watts G. F. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes // Clin. Ther. 2013. Vol. 35, N 8. P. 1082–1098.
17. Sullivan D., Olsson A. G., Scott R. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial // JAMA. 2012. Vol. 308, N 23. P. 2497–2506.
18. Stroes E., Colquhoun D., Sullivan D. et al. Anti-PCSK9 antibodyeffectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placeboc ontrolled phase 3 clinical trial of evolocumab // J. Am. Coll. Cardiol. 2014. Vol. 63, N 23. P. 2541–2548.
19. Koren M. J., Lundqvist P., Bolognese M. et al. Anti-PCSK9 monotherapy for hypercholesterolemia – the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab // J. Am. Coll. Cardiol. 2014. Vol. 63, N 23. P. 2531–2540.
20. Raal F. J., Honarpour N., Blom D. J. et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial // Lancet. 2015. Vol. 385. P. 341–350.
21. Blom D. J., Hala T., Bolognese M. et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia // N. Engl. J. Med. 2014. Vol. 370, N 19. P.1809–1819.
22. Trial assessing long term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSIG). http://clinicaltrials.gov/show/NCT01624142 (accessedAug 9, 2014).
23. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). http://clinicaltrials.gov/ct2/show/NCT01764633 (accessed Aug 9, 2014).
24. Global Assessment of Plaque regression With a PCSK9 antibody as Measured by intravascular Ultrasound (GLAGOV). https://clinicaltrials.gov/ct2/show/NCT01813422.
25. Gusarova V., Howard V. G., Okamoto H. et al. Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates // Clin. Lipid. 2012.
26. Schaefer H., Falk E., Herling A. W. et al. Cholesterollowering effect of SAR236553/REGN727 in hamster after single s. c. injection // Drugs affecting lipid metabolism XVII international symposium e diabetes, obesity and the metabolic syndrome. Doha: Qatar. 2011. March. P. 14–16.
27. Roth E. M., McKenney J. M., Hanotin C. et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia // N. Engl. J. Med. 2012. Vol. 367, N 20. P. 1891–1900.
28. Robinson J. G., Farnier M., Krempf M. et al. Long-term safety, tolerability and efficacy of alirocumab versus placebo in 2,341 high cardiovascular risk patients: ODYSSEY LONG TERM // Latebreaking trial presentation at the American Heart Association 2014 Scientific Sessions.
29. Moriarty P. M., Thompson P. D., Cannon C. P. et al. ODYSSEY ALTERNATIVE: Efficacy and safety of the proprotein convertasesubtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm // Ibid.
30. Bays H., Farnier M., Weiss R. et al. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II // Ibid.
31. Schwartz G. G., Bessac L., Berdan L. G. et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial // Am. Heart J. 2014. Vol. 168, N 5. P. 682–689.
32. Ballantyne Ch. M., Neutel J., Cropp A. et. al. Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia // Am. J. Cardiol. 2015. Vol. 115, N 9. P. 1212–1221.
33. Marais A. D., Kim J. B., Wasserman S. M., Lambert G. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels // Pharmacology & Therapeutics. 2015. Vol. 145. P. 58–66.
Review
For citations:
Astrakova K.S., Ragino Yu.I., Shakhtshneider E.V., Voevoda M.I. Clinical studies of monoclonal antibodies against the proprotein convertase subtilisin / kexin type 9. Ateroscleroz. 2015;11(2):43-49. (In Russ.)
Views:
323
Email this article 